TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05881720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril / Valsartan Oral Tablet
Description: Group 1 (N = 40) received sacubitril/valsartan (target dose, 100 mg twice daily) in addition to recommended therapy according to physician's judgment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg
Description: group 2 received valsartan (N=40, target dose, 80 mg twice daily) in addition to recommended therapy according to physician's judgment.
Study: NCT05291936

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRECISION1® for Astigmatism Contact Lenses
Description: TEST

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRECISION1® for Astigmatism Contact Lenses
Description: TEST

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyDay® Toric Soft Contact Lenses
Description: CONTROL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyDay® Toric Soft Contact Lenses
Description: CONTROL
Study: NCT05092165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylene Blue
Description: 1 mg per kilogram bolus, followed by 0.1 milligram per kilogram during renal replacement therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Usual care during renal replacement therapy
Study: NCT05590000

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gemini SCS neuromodulation system
Description: This neurostimulation system is indicated as an aid in the management of chronic, intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back and leg pain, angina pectoris and peripheral vascular disease.
Study: NCT04104659

Intervention type: DRUG
Intervention: MK 6240
Description: PET tracer, \[18F\]MK-6240 (an\[18F\]tau imaging agent,CerveauTechnologies)that has high affinity for the human phosphorylated tau deposits in AD brain offers new opportunities to investigate tau pathology.(Hostetler, Walji et al. 2016, Lohith, Bennacef et al. 2016, Walji, Hostetler et al. 2016, Lohith, Bennacef et al. 2017, Neelamegam, Yokell et al. 2017).We will evaluate this imaging agent in individuals from families with a known Autosomal Dominant Alzheimer's Disease (ADAD) mutation.~The planned dosage for \[18F\]MK-6240 is a single intravenous bolus injection of 185 MBq (5.0 mCi) in a large peripheral vein followed by a 10 mL normal saline (0.9% NaCl) flush.
Study: NCT06373770

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ayres sensory integration therapy
Description: A. Jean Ayres, is a theory and practice that targets a person's ability to process and internally integrate sensory information from their body and environment. Sensory information may be visual, auditory, tactile, proprioceptive, and/or vestibular in nature. ASI uses individually tailored activities that utilize just right challenges to an individual's existing patterns of sensory processing and motor planning and encourage movement and organization of self in time and space. ASI incorporates specialized equipment and materials in purposeful and playful activities in order to improve adaptive behavior.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Behaviour Therapy
Description: The current treatment options for the core symptoms of autism are limited to psychosocial therapies, such as applied behavior analysis. Medications have been most effective in treating the associated behavioral symptoms of autism, though studies have examined potential benefits in some of the core symptoms of autism with certain medications, especially the repetitive behaviors often seen with this diagnosis. Risperidone and aripiprazole are currently the only medications FDA approved for symptoms associated with autism spectrum disorders, targeting the irritability often seen with this diagnosis.
Study: NCT06020846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soleus Pushup Exercise
Description: Patient will be seated on a chair, his legs at 90 degrees to the floor, keep the toes, and feet flat on the ground, and move his heels up and down continuously.~4 sets of 15 minutes each,1hour total intervention time

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treadmill walk group 2
Description: The patient will do treadmill walk at normal walking speed, 4 sets of treadmill walk for 15 minutes each, 1hour total intervention time
Study: NCT06515314

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFP Specific T Cell Receptor T Cells
Description: AFP Specific T Cell Receptor T Cells On day 1, the TCR-T cells will be administered intravenously.~Drug: Fludarabine + Cyclophosphamide Fludarabine: 25mg/m²/day×3days; Cyclophosphamide: 250mg/m²/day×3 days
Study: NCT05510661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Export Catheter
Description: Manual thrombus aspiration with the use of export catheter during primary PCI

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon catheter
Description: Predilatation with balloon catheter
Study: NCT05466695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 5mg/sildenafil 25 mg
Description: patients will use daily tadalafil or daily sildenafil for 2 months blood sample will be obtained before and after 2 months and also IIEF-5 score for clinical response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 5mg/sildenafil 25 mg
Description: patients will use daily tadalafil or daily sildenafil for 2 months blood sample will be obtained before and after 2 months and also IIEF-5 score for clinical response
Study: NCT05483855

Intervention type: OTHER
Intervention: Objective 2 Only: ArthritisPower Joint Assessment
Description: RA patients must complete a self-assessment examination of their joints using the ArthritisPower app prior to their in-office visit, where a repeat joint assessment is performed by participating physician.
Study: NCT05221775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: XELOX regimen combined with GLS-010 and different doses of Lenvatinib
Study: NCT04965077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Humanized Monoclonal Antibody MIL97 for Injection
Description: Dose escalation phase: The patients confirming to the eligibility criteria will be assigned to the 6 dose groups (0.01mg/kg, 0.03mg/kg, 0.1mg/kg, 0.2mg/kg, 0.3mg/kg 0.45mg/kg, respectively) based on the sequence of inclusion. Each patient will receive an intravenous infusion of MIL97 every 3 week on Day 1 of each cycle. Additional 1 or 2 dose cohorts will receive an intravenous infusion of MIL97 every 2 week on Day 1 of each cycle after last patient finishes DLT observation period.~Dose expansion phase: One or two recommended expansion doses (either Q3W or Q2W) will be selected from 6 dose groups (0.01mg/kg, 0.03mg/kg, 0.1mg/kg, 0.2mg/kg, 0.3mg/kg 0.45mg/kg) based on results of dose escalation phase. MIL97 will be administered via intravenous infusion for 60 to 90 minutes on Day 1 of each cycle.
Study: NCT06070558

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI with Real Time MRI Rapid Flash sequence
Description: MRI examination of temporomandibular joint with Real Time MRI Rapid Flash sequence
Study: NCT05933629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online EmReg
Description: A Web-based group intervention to improve emotion regulation in individuals with traumatic brain injury (TBI). Online EmReg is a 3-hour on-demand training workshop
Study: NCT05933629

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online EmReg
Description: A Web-based group intervention to improve emotion regulation in individuals with traumatic brain injury (TBI). Online EmReg is a 3-hour on-demand training workshop

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consultation Sessions
Description: 3 months of bi-weekly consultation sessions
Study: NCT05449275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Faradic current
Description: The most common Electrical stimulation applied for foot drop is faradic current. Faradic current provides the strength and improvement to volitational muscles and increase the coordination and reduce spasticity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ankle foot orthosis
Description: AFO is most commonly used technique but it also has some disadvantage mainly is the movement in limited direction and also in development of contractures and may have the problem in standing from chair
Study: NCT05995977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing interventions based on protection motivation theory in patients with hypertension
Description: The intervention consists of two components and is planned to last 14 weeks. The first component consists of hypertension education based on the Protection Motivation Theory. The second component is the sending of regularly delivered Protection Motivation Theory-based SMS messages aimed at reminding, encouraging, and motivating patients to maintain medication adherence and healthy lifestyle changes.
Study: NCT05736939

Intervention type: OTHER
Intervention: Out-patient Pulmonary Rehabilitation
Description: Pulmonary Rehabilitation (PR) programme consisting of 30 minutes interval aerobic exercise on cycle ergometers at 100% of peak work rate (WRpeak) and resistance exercises for the upper body. Dyspnoea and leg discomfort were recorded on the modified 1-10 Borg scale, whereas heart rate (HR) and oxygen saturation (SpO2%) were monitored by a pulse oximeter. Based on symptoms of breathlessness and fatigue reported at the end of each session, the exercise intensity was increased by 5-10% of the baseline WRpeak in the next session. The remote 24 home-based PR sessions consisted of 30 minutes walking with an individualised target of steps, recorded via the mobile app installed in the patients' mobile phone. The steps, leg discomfort and dyspnoea were reported by the patient via a physical activity diary on a weekly basis. If dyspnoea and fatigue were both \<4 at the Borg scale the weekly target of steps was increased by 5-10% by the assessors.

Intervention type: OTHER
Intervention: Out-patient Pulmonary Rehabilitation
Description: Pulmonary Rehabilitation (PR) programme consisting of 30 minutes interval aerobic exercise on cycle ergometers at 100% of peak work rate (WRpeak) and resistance exercises for the upper body. Dyspnoea and leg discomfort were recorded on the modified 1-10 Borg scale, whereas heart rate (HR) and oxygen saturation (SpO2%) were monitored by a pulse oximeter. Based on symptoms of breathlessness and fatigue reported at the end of each session, the exercise intensity was increased by 5-10% of the baseline WRpeak in the next session. The remote 24 home-based PR sessions consisted of 30 minutes walking with an individualised target of steps, recorded via the mobile app installed in the patients' mobile phone. The steps, leg discomfort and dyspnoea were reported by the patient via a physical activity diary on a weekly basis. If dyspnoea and fatigue were both \<4 at the Borg scale the weekly target of steps was increased by 5-10% by the assessors.
Study: NCT04751097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CUSH Health Digital platform
Description: Remote mobility monitoring and physiotherapy video app
Study: NCT06213337

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot care training with virtual classroom
Description: Providing foot care training once every two weeks in virtual classes created via the Google meet application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot care training with SMS support
Description: Total of 60 SMS messages containing foot care information will be sent, one every day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot care training with virtual classroom and SMS support
Description: Providing foot care training once every two weeks in virtual classes created via the Google meet application. Furthermore, total of 60 SMS messages containing foot care information will be sent, one every day.
Study: NCT06477549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride
Description: Days -7 through -6: Bendamustine 90 mg/m2 iv x 2 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ruxolitinib
Description: Days -7 through -2: ruxolitinib 5 mg tid per os
Study: NCT04482413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AstroStem
Description: Treatment group receive AstroStem(Autologous adipose tissue derived mesenchymal stem cells, AdMSCs) every 4 weeks from Week 0 to Week 36.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control group receive 20 mL of Saline and auto serum every 4 weeks from Week 0 to Week 36.
Study: NCT04885673

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vapotherm
Description: flow rate 50 L/min with 100% humidified oxygen and the temperature adjusted to be 38℃

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Apneic oxygenation
Description: Standard apneic oxygenation through the side port of rigid bronchoscope during the procedure
Study: NCT04952792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 milligram Oral Tablet
Description: Apixaban 2.5mg/12h, oral, 28 days
Study: NCT05902533

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation (reduced elective nodal dose (30.6 Gy)
Description: 28-30 fractions Monday through Friday of intended chemoradiation depending on the total dose required (50.4-54 Gy) which will occur over approximately 5.5 to 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 825 mg/m2 BID (Oral Twice daily on days with RT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin c
Description: 10 mg/m2 slow IV push Day 1 and 29
Study: NCT04704206

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Children will perform activities on interactive tablet
Description: The main difference between the types of interventions is the mode of use and the level of interactivity of the interactive media, where the AIMG actively performs activities, that is, there is user interaction with the equipment through touch or verbal response and the performance of activities like rotating an object, dragging and zooming. PIMG is not the same, the user is just a spectator, having contact with the equipment only when switching on / off, choosing the content, performing activities such as increasing / decreasing the volume and touching certain specific objects such as giving play / pause . Both groups will have a total of 48 intervention sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Children will perform activities on interactive tablet
Description: The main difference between the types of interventions is the mode of use and the level of interactivity of the interactive media, where the AIMG actively performs activities, that is, there is user interaction with the equipment through touch or verbal response and the performance of activities like rotating an object, dragging and zooming. PIMG is not the same, the user is just a spectator, having contact with the equipment only when switching on / off, choosing the content, performing activities such as increasing / decreasing the volume and touching certain specific objects such as giving play / pause . Both groups will have a total of 48 intervention sessions.
Study: NCT05592600

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Participants will visualize real-time feedback of signals recorded from their brains as measured with functional MRI.
Study: NCT06518707

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phrenic nerve stimulation
Description: A commercial phrenic nerve stimulation equipment will be used during surgery. Phrenic nerve stimulation intensity will be determined before surgery, ensuring significant diaphragm contraction under stimulation. The use of an electric knife will be avoided during surgery. Tidal volume, airway pressure, and vital signs will be monitored continuously.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phrenic nerve stimulation
Description: A commercial phrenic nerve stimulation equipment will be used during surgery. Phrenic nerve stimulation intensity will be determined before surgery, ensuring significant diaphragm contraction under stimulation. The use of an electric knife will be avoided during surgery. Tidal volume, airway pressure, and vital signs will be monitored continuously.
Study: NCT06105658

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Unrelated umbilical cord blood
Description: The requirements of unrelated umbilical cord blood: recipient-donor HLA match is 0-3/10, same blood type.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Patients will be treated with Venetoclax (100 mg on day 1, 200 mg on day 2 and 400 mg on days 3 to 21)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decetabine
Description: Patients will be treated with Decetabine (20mg/m\^2/d on days 1 to 5) or Azacitidine (75mg/m\^2/d on days 1 to 7)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Patients will be treated with Decetabine (20mg/m\^2/d on days 1 to 5) or Azacitidine (75mg/m\^2/d on days 1 to 7)
Study: NCT05667441

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard lifestyle recommendations + dietary supplementation
Description: refrain from smoking; perform physical exercise regularly; increase the intake of dietary food groups such as green leafy vegetables, fruits, and fatty fish and recommendations for supplementation with antioxidants according an established formula

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard lifestyle recommendations + dietary supplementation
Description: refrain from smoking; perform physical exercise regularly; increase the intake of dietary food groups such as green leafy vegetables, fruits, and fatty fish and recommendations for supplementation with antioxidants according an established formula
Study: NCT05117021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caudal Epidural Block using 0.25% plain bupivacaine dose 1 ml / kg and Ultrasound Guided Transversus Abdominis Plane Block using 0.25% plain bupivacaine dose 0.5 ml / kg
Description: Caudal Epidural Block and Ultrasound Guided Transversus Abdominis Plane Block using 0.25% plain bupivacaine
Study: NCT05667441

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard lifestyle recommendations + dietary supplementation
Description: refrain from smoking; perform physical exercise regularly; increase the intake of dietary food groups such as green leafy vegetables, fruits, and fatty fish and recommendations for supplementation with antioxidants according an established formula
Study: NCT06158230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pizotifen
Description: Pizotifen will be given only at night time to avoid daytime somnolence. Starting dose will be 0.5mg then gradually increased to 1.5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline-propranolol
Description: Amitriptyline will be given at bedtime only, starting at 10 mg daily and gradually increasing to 25 mg daily.~Propranolol will be started in 40 mg daily in divided doses, which gradually increases to 80 mg daily in divided doses
Study: NCT05561465

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pterygomaxillary disjunction with interposition Y-shape plate
Description: All patients will be treated under general anesthesia. The pterygoid plate will be fractured, pried up, and pushed backward. A Y-shape plate will be fixed to the lateral maxillary surface with its vertical limb and the other two limbs are turned to fit into the retro maxillary space preventing the reattachment of the fractured pterygoid plate
Study: NCT06461728

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a new prototye device that heat and activate sodium hyochlorite (Aseptico)
Description: endoactivator : it is a sonic activator device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: a new prototye device that heat and activate sodium hyochlorite (Aseptico)
Description: endoactivator : it is a sonic activator device
Study: NCT06355115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin 1000 MG Injection
Description: Cefazolin 1000 mg given intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin 1000 MG Injection
Description: Cefazolin 1000 mg given intravenously
Study: NCT04152603

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRIEF Educational Module
Description: The BRIEF Educational Module for research recruitment team members is intended to teach evidence-based approaches to improving participant experiences with research recruitment. It has three components: (1) asynchronous pre-work, including multimedia materials and an individual worksheet (approx. 30 min); (2) one synchronous in-person (or virtual if necessary) session, including didactics, discussions, and practice scenarios (approx. 90 min); and (3) an asynchronous, individual follow-up phone call to review individual questions (approx. 15 min).
Study: NCT06490263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Mulberry Twig Alkaloids Tablets 126 mg single dose in healthy subjects
Description: Part One: Administered by chewing with meals or swallowing after meals, with a dosage of 126 milligrams, given as a single dose only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mulberry Twig Alkaloids Tablets with single dose in healthy subjects
Description: Parts Two: Administered by swallowing after meals with four distinct dosage groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mulberry Twig Alkaloids Tablets with multiple dose in healthy subjects
Description: Part Three: Administered by swallowing after meals with two distinct dosage groups, taken three times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mulberry Twig Alkaloids Tablets with multiple dose in overweight or obese subjects
Description: Part Three: Administered by swallowing after meals with two distinct dosage groups, taken three times daily.
Study: NCT04537000

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: clinical condition score
Description: A score is firstly identified using a clinical condition scale including the concentration of inspired oxygen to maintain the percutaneous oxygen saturation (SPO2)≧95%, the fusion rate of catecholamine drugs to maintain normal blood pressure, the nasopharyngeal temperature and the oxygen saturation of central venous blood. The score was graded as 0, 1 and 2 points according to the patient's clinical condition. The score identified from the scale plus 7 finally makes the clinical condition score. If the score is higher than 10, it will be replaced with 10. That is to say, the highest clinical condition score is 10. If the clinical condition score≦Hb, blood red cell transfusion will not be started. If the clinical condition score\>Hb, blood red cell transfusion will be started, and the volume will be calculated using the following formulation, transfusion volume(ml)=(clinical condition score - Hb)\*body weight \*5.